Haemonetics (HAE)
Haemonetics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, financials, earnings dates and insider trades. Listed on NYSE, classified by the SEC as surgical & medical instruments & apparatus.
3.4M
Short interest
settlement 2026-10-15
3.9
Days to cover
-1.4 days vs prior
49.5%
Short share of volume
2026-11-02
211
Fails to deliver
settlement 2026-10-09
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in HAE is 3,428,091 shares, up 3,395 shares over the last month. Over the last 48 readings it ranged from 1,904,947 shares (13 March 2026) to 6,832,676 shares (14 February 2025). At the reported average volume of 881K shares a day that is 3.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/hae" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 3,428,091 | +12.8% | 881,291 | 3.89 |
| 2026-09-30 | 3,037,763 | -11.3% | 569,315 | 5.34 |
| 2026-09-15 | 3,424,696 | +19.6% | 602,088 | 5.69 |
| 2026-08-31 | 2,863,501 | +3.7% | 841,772 | 3.40 |
| 2026-08-14 | 2,761,115 | -5.5% | 888,797 | 3.11 |
| 2026-07-31 | 2,921,809 | +8.2% | 638,654 | 4.57 |
| 2026-07-15 | 2,701,605 | -7.3% | 640,781 | 4.22 |
| 2026-06-30 | 2,914,882 | -3.3% | 931,315 | 3.13 |
| 2026-06-15 | 3,013,604 | +1.9% | 1,117,697 | 2.70 |
| 2026-05-29 | 2,956,590 | +14.5% | 953,923 | 3.10 |
| 2026-05-15 | 2,583,187 | +30.4% | 1,061,034 | 2.43 |
| 2026-04-30 | 1,980,212 | -0.8% | 680,608 | 2.91 |
| 2026-04-15 | 1,995,363 | -3.8% | 541,640 | 3.68 |
| 2026-03-31 | 2,073,575 | +8.8% | 813,418 | 2.55 |
| 2026-03-13 | 1,904,947 | -29.7% | 787,145 | 2.42 |
| 2026-02-27 | 2,709,643 | +6.8% | 783,083 | 3.46 |
| 2026-02-13 | 2,537,146 | +5.2% | 1,265,629 | 2.00 |
| 2026-01-30 | 2,411,300 | -21.6% | 926,738 | 2.60 |
| 2026-01-15 | 3,077,776 | -11.8% | 723,301 | 4.26 |
| 2025-12-31 | 3,491,564 | +3.0% | 569,544 | 6.13 |
| 2025-12-15 | 3,389,295 | -6.4% | 882,555 | 3.84 |
| 2025-11-28 | 3,621,526 | +21.0% | 813,167 | 4.45 |
| 2025-11-14 | 2,991,990 | -4.2% | 1,593,621 | 1.88 |
| 2025-10-31 | 3,123,353 | -6.4% | 561,272 | 5.56 |
| 2025-10-15 | 3,337,057 | +6.5% | 735,969 | 4.53 |
| 2025-09-30 | 3,133,216 | -7.6% | 1,265,153 | 2.48 |
| 2025-09-15 | 3,392,408 | -7.5% | 950,495 | 3.57 |
| 2025-08-29 | 3,667,472 | -16.1% | 961,752 | 3.81 |
| 2025-08-15 | 4,370,093 | +42.0% | 1,609,897 | 2.71 |
| 2025-07-31 | 3,077,957 | -12.1% | 537,406 | 5.73 |
| 2025-07-15 | 3,500,606 | -4.5% | 561,893 | 6.23 |
| 2025-06-30 | 3,664,140 | -9.7% | 589,508 | 6.22 |
| 2025-06-13 | 4,059,388 | -1.4% | 507,641 | 8.00 |
| 2025-05-30 | 4,118,270 | +1.1% | 455,529 | 9.04 |
| 2025-05-15 | 4,075,152 | -6.4% | 685,512 | 5.94 |
| 2025-04-30 | 4,353,951 | -1.8% | 500,541 | 8.70 |
| 2025-04-15 | 4,432,305 | -2.2% | 898,875 | 4.93 |
| 2025-03-31 | 4,530,482 | -24.9% | 662,610 | 6.84 |
| 2025-03-14 | 6,028,768 | -6.8% | 918,847 | 6.56 |
| 2025-02-28 | 6,468,224 | -5.3% | 982,992 | 6.58 |
| 2025-02-14 | 6,832,676 | +30.3% | 1,781,301 | 3.84 |
| 2025-01-31 | 5,242,500 | +5.7% | 882,077 | 5.94 |
| 2025-01-15 | 4,959,780 | -5.2% | 418,431 | 11.85 |
| 2024-12-31 | 5,229,686 | +6.5% | 497,050 | 10.52 |
| 2024-12-13 | 4,908,199 | +7.5% | 497,576 | 9.86 |
| 2024-11-29 | 4,567,100 | -0.3% | 530,861 | 8.60 |
| 2024-11-15 | 4,581,509 | -11.2% | 913,522 | 5.02 |
| 2024-10-31 | 5,161,496 | -1.9% | 471,213 | 10.95 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of HAE volume is 49.5%, up 3.6 points over the last five sessions. Over the last 30 readings it ranged from 28.5% (5 October 2026) to 75.0% (27 October 2026). The latest reading is 2.3 points above the 30-session average of 47.2%, on 207K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 102K | 207K | 49.5% | 30 |
| 2026-10-30 | 93K | 166K | 55.9% | 8,600 |
| 2026-10-29 | 65K | 155K | 42.1% | 189 |
| 2026-10-28 | 118K | 210K | 56.1% | 0 |
| 2026-10-27 | 327K | 437K | 75.0% | 0 |
| 2026-10-26 | 68K | 148K | 45.9% | 0 |
| 2026-10-23 | 120K | 375K | 32.1% | 0 |
| 2026-10-22 | 71K | 141K | 50.1% | 0 |
| 2026-10-21 | 305K | 476K | 64.0% | 0 |
| 2026-10-20 | 87K | 220K | 39.5% | 0 |
| 2026-10-19 | 77K | 153K | 50.0% | 0 |
| 2026-10-16 | 75K | 200K | 37.6% | 0 |
| 2026-10-15 | 117K | 325K | 36.0% | 0 |
| 2026-10-14 | 136K | 246K | 55.5% | 0 |
| 2026-10-13 | 213K | 357K | 59.7% | 1,490 |
| 2026-10-12 | 236K | 447K | 52.9% | 0 |
| 2026-10-09 | 277K | 497K | 55.8% | 0 |
| 2026-10-08 | 740K | 1.4M | 54.4% | 52 |
| 2026-10-07 | 91K | 167K | 54.2% | 0 |
| 2026-10-06 | 54K | 131K | 41.3% | 0 |
| 2026-10-05 | 53K | 187K | 28.5% | 0 |
| 2026-10-02 | 63K | 114K | 55.3% | 0 |
| 2026-10-01 | 95K | 189K | 50.2% | 12,800 |
| 2026-09-30 | 50K | 147K | 34.3% | 0 |
| 2026-09-29 | 121K | 196K | 61.7% | 5,100 |
| 2026-09-28 | 85K | 200K | 42.6% | 26,000 |
| 2026-09-25 | 49K | 172K | 28.8% | 0 |
| 2026-09-24 | 52K | 168K | 31.0% | 621 |
| 2026-09-23 | 129K | 350K | 36.9% | 0 |
| 2026-09-22 | 62K | 158K | 39.5% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 9 October 2026, the fails-to-deliver balance in HAE is 211 shares, up 167 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (22 January 2026) to 73,355 shares (13 May 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-09 | 211 | $119.47 | $25K |
| 2026-09-25 | 44 | $106.00 | $5K |
| 2026-09-21 | 186 | $108.40 | $20K |
| 2026-08-21 | 1,894 | $108.22 | $205K |
| 2026-08-12 | 37 | $87.22 | $3K |
| 2026-06-22 | 500 | $74.17 | $37K |
| 2026-06-15 | 584 | $78.20 | $46K |
| 2026-06-10 | 247 | $78.71 | $19K |
| 2026-06-03 | 6,745 | $66.37 | $448K |
| 2026-06-02 | 408 | $67.22 | $27K |
| 2026-06-01 | 318 | $67.81 | $22K |
| 2026-05-29 | 34 | $67.04 | $2K |
| 2026-05-22 | 136 | $61.94 | $8K |
| 2026-05-19 | 21 | $57.28 | $1K |
| 2026-05-15 | 81 | $57.12 | $5K |
| 2026-05-13 | 73,355 | $54.01 | $4.0M |
| 2026-05-11 | 3,419 | $55.12 | $188K |
| 2026-05-05 | 3,438 | $55.32 | $190K |
| 2026-04-22 | 75 | $60.21 | $5K |
| 2026-03-17 | 6,981 | $59.70 | $417K |
| 2026-03-12 | 659 | $60.62 | $40K |
| 2026-03-10 | 7,537 | $64.23 | $484K |
| 2026-02-27 | 218 | $62.24 | $14K |
| 2026-02-06 | 15 | $65.02 | $975 |
| 2026-01-22 | 1 | $70.11 | $70 |
| 2025-12-05 | 36 | $83.81 | $3K |
| 2025-11-21 | 618 | $75.12 | $46K |
| 2025-11-17 | 185 | $73.49 | $14K |
| 2025-11-14 | 185 | $73.91 | $14K |
| 2025-11-07 | 4,686 | $67.11 | $314K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for HAE in the last 90 days. The most recent filings are listed below. Latest filing: Madaus Martin D (Director) on 2026-07-24.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-07-24 | Madaus Martin D | Director | Grant | 3K | price not stated in the filing | not stated | 3K |
| 2026-07-24 | Zane Ellen M | Director | Grant | 3K | price not stated in the filing | not stated | 22K |
| 2026-07-24 | Pomeroy Claire | Director | Grant | 3K | price not stated in the filing | not stated | 19K |
| 2026-07-24 | KROLL MARK W | Director | Grant | 3K | price not stated in the filing | not stated | 27K |
| 2026-07-24 | Johnson Lloyd Emerson | Director | Grant | 3K | price not stated in the filing | not stated | 15K |
| 2026-07-24 | COYLE MICHAEL J | Director | Grant | 3K | price not stated in the filing | not stated | 18K |
| 2026-07-24 | Bryant Diane M | Director | Grant | 3K | price not stated in the filing | not stated | 10K |
| 2026-07-24 | ABERNATHY ROBERT E | Director | Grant | 3K | price not stated in the filing | not stated | 28K |
| 2026-06-05 | Maunsell Farris Maryanne | VP, Chief Accounting Officer | Tax withholding | 259 | $71.28 | $18K | 6K |
| 2026-06-05 | Miller Laurie A. | SVP, Human Resources | Tax withholding | 313 | $71.28 | $22K | 41K |
| 2026-05-15 | Simon, Christopher | President & CEO | Grant | 78K | price not stated in the filing | not stated | 445K |
| 2026-05-15 | Miller Laurie A. | SVP, Human Resources | Grant | 13K | price not stated in the filing | not stated | 41K |
| 2026-05-15 | Galvin Roy | EVP, Chief Commercial Officer | Grant | 28K | price not stated in the filing | not stated | 40K |
| 2026-05-15 | Maunsell Farris Maryanne | VP, Chief Accounting Officer | Grant | 2K | price not stated in the filing | not stated | 7K |
| 2026-05-15 | DArecca James | EVP, Chief Financial Officer | Grant | 29K | price not stated in the filing | not stated | 54K |
| 2026-05-15 | Chan Frank | EVP, Chief Operating Officer | Grant | 28K | price not stated in the filing | not stated | 33K |
| 2026-05-15 | Basil Michelle L | EVP and General Counsel | Grant | 28K | price not stated in the filing | not stated | 69K |
| 2026-05-15 | Maunsell Farris Maryanne | VP, Chief Accounting Officer | Tax withholding | 197 | $56.29 | $11K | 4K |
| 2026-05-15 | Miller Laurie A. | SVP, Human Resources | Tax withholding | 948 | $56.29 | $53K | 28K |
| 2026-05-15 | Simon, Christopher | President & CEO | Tax withholding | 10K | $56.29 | $545K | 366K |
| 2026-05-15 | Galvin Roy | EVP, Chief Commercial Officer | Tax withholding | 879 | $56.29 | $49K | 12K |
| 2026-05-15 | DArecca James | EVP, Chief Financial Officer | Tax withholding | 3K | $56.29 | $141K | 25K |
| 2026-05-15 | Chan Frank | EVP, Chief Operating Officer | Tax withholding | 546 | $56.29 | $31K | 5K |
| 2026-05-15 | Basil Michelle L | EVP and General Counsel | Tax withholding | 3K | $56.29 | $164K | 40K |
| 2026-05-01 | DArecca James | EVP, Chief Financial Officer | Tax withholding | 655 | $59.26 | $39K | 28K |
| 2025-11-10 | KROLL MARK W | Director | Buy | 1K | $70.56 | $99K | 25K |
| 2025-10-31 | Galvin Roy | EVP, Chief Commercial Officer | Tax withholding | 145 | $50.01 | $7K | 13K |
| 2025-09-17 | Miller Laurie A. | SVP, Human Resources | Tax withholding | 238 | $49.95 | $12K | 29K |
| 2025-07-24 | ABERNATHY ROBERT E | Director | Grant | 3K | price not stated in the filing | not stated | 25K |
| 2025-07-24 | Bryant Diane M | Director | Grant | 3K | price not stated in the filing | not stated | 7K |
| 2025-07-24 | COYLE MICHAEL J | Director | Grant | 3K | price not stated in the filing | not stated | 15K |
| 2025-07-24 | Dockendorff Charles J | Director | Grant | 3K | price not stated in the filing | not stated | 7K |
| 2025-07-24 | Johnson Lloyd Emerson | Director | Grant | 3K | price not stated in the filing | not stated | 13K |
| 2025-07-24 | KROLL MARK W | Director | Grant | 3K | price not stated in the filing | not stated | 23K |
| 2025-07-24 | Pomeroy Claire | Director | Grant | 3K | price not stated in the filing | not stated | 17K |
| 2025-07-24 | Zane Ellen M | Director | Grant | 3K | price not stated in the filing | not stated | 19K |
| 2025-06-05 | Maunsell Farris Maryanne | VP, Chief Accounting Officer | Grant | 3K | price not stated in the filing | not stated | 4K |
| 2025-06-05 | Miller Laurie A. | SVP, Human Resources | Grant | 3K | price not stated in the filing | not stated | 29K |
| 2025-05-30 | Basil Michelle L | EVP and General Counsel | Tax withholding | 7K | $69.38 | $518K | 42K |
| 2025-05-30 | Basil Michelle L | EVP and General Counsel | Grant | 16K | $0.00 | $0 | 50K |
| 2025-05-30 | DArecca James | EVP, Chief Financial Officer | Grant | 12K | $0.00 | $0 | 34K |
| 2025-05-30 | DArecca James | EVP, Chief Financial Officer | Tax withholding | 6K | $69.38 | $407K | 28K |
| 2025-05-30 | Miller Laurie A. | SVP, Human Resources | Grant | 8K | $0.00 | $0 | 28K |
| 2025-05-30 | Miller Laurie A. | SVP, Human Resources | Tax withholding | 2K | $69.38 | $158K | 26K |
| 2025-05-30 | Simon, Christopher | President & CEO | Grant | 67K | $0.00 | $0 | 402K |
| 2025-05-30 | Simon, Christopher | President & CEO | Tax withholding | 26K | $69.38 | $1.8M | 376K |
| 2025-05-16 | Simon, Christopher | President & CEO | Tax withholding | 7K | $70.31 | $498K | 314K |
| 2025-05-16 | Miller Laurie A. | SVP, Human Resources | Tax withholding | 477 | $70.31 | $34K | 17K |
| 2025-05-16 | Galvin Roy | President, Global Plasma & BC | Tax withholding | 257 | $70.31 | $18K | 7K |
| 2025-05-16 | Maunsell Farris Maryanne | VP, Chief Accounting Officer | Tax withholding | 68 | $70.31 | $5K | 1K |
| 2025-05-16 | DArecca James | EVP, Chief Financial Officer | Tax withholding | 1K | $70.31 | $88K | 15K |
| 2025-05-16 | Basil Michelle L | EVP and General Counsel | Tax withholding | 2K | $70.31 | $152K | 28K |
| 2025-05-16 | Simon, Christopher | President & CEO | Grant | 21K | price not stated in the filing | not stated | 335K |
| 2025-05-16 | DArecca James | EVP, Chief Financial Officer | Grant | 7K | price not stated in the filing | not stated | 22K |
| 2025-05-16 | Basil Michelle L | EVP and General Counsel | Grant | 6K | price not stated in the filing | not stated | 34K |
| 2025-05-16 | Galvin Roy | President, Global Plasma & BC | Grant | 7K | price not stated in the filing | not stated | 14K |
| 2025-05-16 | Chan Frank | EVP, Chief Operating Officer | Grant | 6K | price not stated in the filing | not stated | 6K |
| 2025-05-16 | Miller Laurie A. | SVP, Human Resources | Grant | 3K | price not stated in the filing | not stated | 20K |
| 2025-05-16 | Maunsell Farris Maryanne | VP, Chief Accounting Officer | Grant | 800 | price not stated in the filing | not stated | 2K |
| 2025-05-16 | Galvin Roy | EVP, Chief Commercial Officer | Grant | 6K | price not stated in the filing | not stated | 13K |
| 2025-05-16 | Basil Michelle L | EVP and General Counsel | Grant | 7K | price not stated in the filing | not stated | 35K |
| 2025-05-15 | Simon, Christopher | President & CEO | Tax withholding | 2K | $69.38 | $166K | 321K |
| 2025-05-15 | Miller Laurie A. | SVP, Human Resources | Tax withholding | 206 | $69.38 | $14K | 18K |
| 2025-05-15 | Galvin Roy | President, Global Plasma & BC | Tax withholding | 201 | $69.38 | $14K | 8K |
| 2025-05-15 | Maunsell Farris Maryanne | VP, Chief Accounting Officer | Tax withholding | 60 | $69.38 | $4K | 1K |
| 2025-05-15 | DArecca James | EVP, Chief Financial Officer | Tax withholding | 622 | $69.38 | $43K | 16K |
| 2025-05-15 | Basil Michelle L | EVP and General Counsel | Tax withholding | 622 | $69.38 | $43K | 31K |
| 2025-05-02 | DArecca James | EVP, Chief Financial Officer | Tax withholding | 654 | $63.85 | $42K | 17K |
| 2024-11-01 | Galvin Roy | President, Global Plasma & BC | Tax withholding | 161 | $71.48 | $12K | 7K |
| 2024-09-17 | Miller Laurie A. | SVP, Human Resources | Tax withholding | 238 | $76.54 | $18K | 18K |
| 2024-08-29 | Simon, Christopher | President & CEO | Other transaction | 40K | $75.56 | $3.0M | 323K |
| 2024-07-26 | Strong Stewart W | President, Global Hospital | Sell | 4K | $91.15 | $393K | 18K |
| 2024-07-25 | Zane Ellen M | Director | Grant | 2K | price not stated in the filing | not stated | 17K |
| 2024-07-25 | Pomeroy Claire | Director | Grant | 2K | price not stated in the filing | not stated | 14K |
| 2024-07-25 | KROLL MARK W | Director | Grant | 2K | price not stated in the filing | not stated | 21K |
| 2024-07-25 | Johnson Lloyd Emerson | Director | Grant | 2K | price not stated in the filing | not stated | 10K |
| 2024-07-25 | Dockendorff Charles J | Director | Grant | 2K | price not stated in the filing | not stated | 4K |
| 2024-07-25 | COYLE MICHAEL J | Director | Grant | 2K | price not stated in the filing | not stated | 13K |
| 2024-07-25 | Bryant Diane M | Director | Grant | 2K | price not stated in the filing | not stated | 4K |
| 2024-07-25 | ABERNATHY ROBERT E | Director | Grant | 2K | price not stated in the filing | not stated | 22K |
| 2024-07-25 | Strong Stewart W | President, Global Hospital | Tax withholding | 3K | $90.58 | $253K | 23K |
| 2024-07-24 | Strong Stewart W | President, Global Hospital | Grant | 7K | $0.00 | $0 | 25K |
| 2024-07-12 | Lingamneni Anila | EVP, Chief Technology Officer | Sell | 79 | $90.00 | $7K | 21K |
| 2024-07-11 | Lingamneni Anila | EVP, Chief Technology Officer | Sell | 2K | $90.00 | $192K | 21K |
| 2024-06-06 | Simon, Christopher | President & CEO | Exercise or conversion | 105K | $41.64 | $4.4M | 434K |
| 2024-06-06 | Simon, Christopher | President & CEO | Tax withholding | 71K | $87.38 | $6.2M | 363K |
| 2024-05-29 | Strong Stewart W | President, Global Hospital | Sell | 9K | $87.53 | $775K | 18K |
| 2024-05-29 | Basil Michelle L | EVP and General Counsel | Sell | 9K | $87.86 | $782K | 35K |
| 2024-05-29 | Basil Michelle L | EVP and General Counsel | Sell | 4K | $88.57 | $363K | 31K |
| 2024-05-28 | Strong Stewart W | President, Global Hospital | Tax withholding | 4K | $95.73 | $421K | 27K |
| 2024-05-28 | Strong Stewart W | President, Global Hospital | Grant | 13K | $0.00 | $0 | 31K |
| 2024-05-28 | Simon, Christopher | President & CEO | Tax withholding | 42K | $95.73 | $4.0M | 329K |
| 2024-05-28 | Simon, Christopher | President & CEO | Grant | 106K | $0.00 | $0 | 371K |
| 2024-05-28 | Miller Laurie A. | SVP, Human Resources | Grant | 3K | $0.00 | $0 | 19K |
| 2024-05-28 | Miller Laurie A. | SVP, Human Resources | Tax withholding | 778 | $95.73 | $74K | 18K |
| 2024-05-28 | Basil Michelle L | EVP and General Counsel | Grant | 25K | $0.00 | $0 | 56K |
| 2024-05-28 | Basil Michelle L | EVP and General Counsel | Tax withholding | 12K | $95.73 | $1.1M | 44K |
| 2024-05-28 | Llorens Josep | EVP, Global Manufacturing | Tax withholding | 5K | $95.73 | $432K | 31K |
| 2024-05-28 | Llorens Josep | EVP, Global Manufacturing | Grant | 14K | $0.00 | $0 | 35K |
| 2024-05-28 | Lingamneni Anila | EVP, Chief Technology Officer | Tax withholding | 5K | $95.73 | $505K | 24K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of HAE in their latest filing, all on Schedule 13G (passive). The largest reported stake is Vanguard Portfolio Management at 5.6% of the class (2,600,145 shares), filed 2026-04-29 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-12 | 13G/Ano. 1 | AQR Capital Management, LLCinvestment adviser | 2.3M | 5.0% | 2026-06-30 |
| 2026-08-12 | 13G/Ano. 1 | AQR Capital Management Holdings, LLCparent holding company | 2.3M | 5.0% | 2026-06-30 |
| 2026-05-13 | 13G/Ano. 1 | Jeremy Steven Kahanparent holding company, individual | 0 | 0.0% | 2026-03-31 |
| 2026-05-13 | 13G/Ano. 1 | Michael Kevin Kahanparent holding company, individual | 0 | 0.0% | 2026-03-31 |
| 2026-05-13 | 13G/Ano. 1 | North Peak Capital Ultra Fund, LPpartnership | 0 | 0.0% | 2026-03-31 |
| 2026-05-13 | 13G/Ano. 1 | North Peak Capital Alpha Fund, LPpartnership | 0 | 0.0% | 2026-03-31 |
| 2026-05-13 | 13G/Ano. 1 | North Peak Capital Partners II, LPpartnership | 0 | 0.0% | 2026-03-31 |
| 2026-05-13 | 13G/Ano. 1 | North Peak Capital Partners, LPpartnership | 0 | 0.0% | 2026-03-31 |
| 2026-05-13 | 13G/Ano. 1 | North Peak Capital GP, LLCother entity | 0 | 0.0% | 2026-03-31 |
| 2026-05-13 | 13G/Ano. 1 | North Peak Capital Management, LLCinvestment adviser, other entity | 0 | 0.0% | 2026-03-31 |
| 2026-04-30 | 13G | Vanguard Capital Managementinvestment adviser | 2.4M | 5.3% | 2026-03-31 |
| 2026-04-29 | 13G | Vanguard Portfolio Managementinvestment adviser | 2.6M | 5.6% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 15 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding HAE at their latest 13F. JSON8 of the 30 tracked managers held HAE at their latest 13F, $347.0M in total at quarter-end prices. AQR Capital Management is the largest at $165.0M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 2.3M | $165.0M | 0.06% | -1.1M |
| Citadel Advisors | 2026-06-30 | 1.5M | $113.3M | 0.01% | +1.3M |
| Millennium Management | 2026-06-30 | 570K | $42.8M | 0.02% | +561K |
| Renaissance Technologies | 2026-06-30 | 130K | $9.8M | 0.01% | +87K |
| Point72 Asset Management | 2026-06-30 | 109K | $8.2M | 0.01% | +52K |
| Bridgewater Associates | 2026-06-30 | 60K | $4.5M | 0.02% | +11K |
| D. E. Shaw & Co. | 2026-06-30 | 36K | $2.7M | 0.00% | -155K |
| Two Sigma Investments | 2026-06-30 | 11K | $794K | 0.00% | -1K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q1 FY 2027 (quarter ended 2026-06-27) Haemonetics reported revenue of $339.4M, up 5.6% from the same quarter a year earlier, and net income of $33.0M (0.72 diluted EPS). In FY 2026 it generated $293.2M of operating cash flow and spent $175.0M on buybacks. As of 2026-06-27, cash was $223.4M against $1.19B of debt.
- Cash
- $223.4M
- Debt
- $1.19B
- Equity
- $837.1M
- Total assets
- $2.37B
- Shares outstanding
- 45,497,051
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q1 FY 2027 | 2026-06-27 | $339.4M | $33.0M | 9.7% | 0.72 |
| Q4 FY 2026derived | 2026-03-28 | $346.4M | -$20.1M | -5.8% | n/a |
| Q3 FY 2026 | 2025-12-27 | $339.0M | $44.7M | 13.2% | 0.95 |
| Q2 FY 2026 | 2025-09-27 | $327.3M | $38.7M | 11.8% | 0.81 |
| Q1 FY 2026 | 2025-06-28 | $321.4M | $34.0M | 10.6% | 0.70 |
| Q4 FY 2025derived | 2025-03-29 | $330.6M | $58.0M | 17.5% | n/a |
| Q3 FY 2025 | 2024-12-28 | $348.5M | $37.5M | 10.8% | 0.74 |
| Q2 FY 2025 | 2024-09-28 | $345.5M | $33.8M | 9.8% | 0.66 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2026 | 2026-03-28 | $1.33B | $97.3M | $293.2M | $32.8M | $175.0M | n/a |
| FY 2025 | 2025-03-29 | $1.36B | $167.7M | $181.7M | $39.3M | $225.0M | n/a |
| FY 2024 | 2024-03-30 | $1.31B | $117.6M | $181.8M | $38.1M | $0 | n/a |
| FY 2023 | 2023-04-01 | $1.17B | $115.4M | $273.1M | $191.3M | $75.0M | n/a |
| FY 2022 | 2022-04-02 | $993.2M | $43.4M | $172.3M | $96.5M | $0 | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-27; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Haemonetics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Haemonetics (HAE), SEC CIK 313143, listed on NYSE, classified by the SEC as surgical & medical instruments & apparatus. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-09.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-12.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-27.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-07-24.JSON and CSV
- Company record
- EDGAR filing index for CIK 313143Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as surgical & medical instruments & apparatus
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of HAE is sold short?
3,428,091 shares were held short at the 2026-10-15 settlement, 3.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is HAE's daily short volume?
On 2026-11-02, 102,459 of the 207,088 HAE shares reported to FINRA were sold short, 49.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does HAE have fails to deliver?
The SEC's latest file shows 211 HAE shares failed to deliver at settlement 2026-10-09. Fails are reported per settlement date and published twice a month with a lag.
Are HAE insiders buying or selling?
No open-market insider trades were reported for HAE in the last 90 days. The most recent filings are listed below. Latest filing: Madaus Martin D (Director) on 2026-07-24.
Who owns 5% or more of HAE?
2 holders report 5% or more of HAE in their latest filing, all on Schedule 13G (passive). The largest reported stake is Vanguard Portfolio Management at 5.6% of the class (2,600,145 shares), filed 2026-04-29 for an event on 2026-03-31.
What did HAE report last quarter?
In Q1 FY 2027 (quarter ended 2026-06-27) Haemonetics reported revenue of $339.4M, up 5.6% from the same quarter a year earlier, and net income of $33.0M (0.72 diluted EPS). In FY 2026 it generated $293.2M of operating cash flow and spent $175.0M on buybacks. As of 2026-06-27, cash was $223.4M against $1.19B of debt.
Which tracked 13F managers own HAE?
8 of the 30 tracked 13F managers held HAE shares at their latest filing, $347.0M in all. The largest: Cliff Asness's AQR Capital Management (2.3M shares, $165.0M), Ken Griffin's Citadel Advisors (1.5M shares, $113.3M), Izzy Englander's Millennium Management (570K shares, $42.8M), Renaissance Technologies (130K shares, $9.8M), Steve Cohen's Point72 Asset Management (109K shares, $8.2M), Ray Dalio's Bridgewater Associates (60K shares, $4.5M). The table above lists all 8.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.